Presentation is loading. Please wait.

Presentation is loading. Please wait.

Correlation between frequency of Th17 cells and disease activity or amount of proteinuria in patients with systemic lupus erythematosus (SLE). Correlation.

Published byGérard Cantin Modified over 5 years ago

Similar presentations

Presentation on theme: "Correlation between frequency of Th17 cells and disease activity or amount of proteinuria in patients with systemic lupus erythematosus (SLE). Correlation."— Presentation transcript:

1 Correlation between frequency of Th17 cells and disease activity or amount of proteinuria in patients with systemic lupus erythematosus (SLE). Correlation between frequency of Th17 cells and disease activity or amount of proteinuria in patients with systemic lupus erythematosus (SLE). There was a positive correlation with linearity between Th17 frequencies and (A) SLE disease activity index scores (SLEDAI) or (B) amount of proteinuria. Ming-Fei Liu, and Chrong-Reen Wang Lupus Sci Med 2014;1:e000062 ©2014 by Lupus Foundation of America

Download ppt "Correlation between frequency of Th17 cells and disease activity or amount of proteinuria in patients with systemic lupus erythematosus (SLE). Correlation."

Similar presentations

Copyright © 2004 American Medical Association. All rights reserved.

Copyright © 2004 American Medical Association. All rights reserved.
Anifrolumab inhibits type I interferon (IFN)-induced IFN-stimulated response element (ISRE) signalling. Anifrolumab inhibits type I interferon (IFN)-induced.

Anifrolumab inhibits type I interferon (IFN)-induced IFN-stimulated response element (ISRE) signalling. Anifrolumab inhibits type I interferon (IFN)-induced.
Time between systemic lupus erythematosus (SLE) and haematological malignancy diagnoses. Time between systemic lupus erythematosus (SLE) and haematological.

Time between systemic lupus erythematosus (SLE) and haematological malignancy diagnoses. Time between systemic lupus erythematosus (SLE) and haematological.
Disease activity over time in autoantibody-positive patients treated with belimumab. Disease activity over time in autoantibody-positive patients treated.

Disease activity over time in autoantibody-positive patients treated with belimumab. Disease activity over time in autoantibody-positive patients treated.
Supplementary Figure 1. Longitudinal study in a representative number of SLE patients one year before (t1), at the time (t2), and one year after renal.

Supplementary Figure 1. Longitudinal study in a representative number of SLE patients one year before (t1), at the time (t2), and one year after renal.
Volume 10, Issue 3, Pages (March 2018)

Volume 10, Issue 3, Pages (March 2018)
Time course for laboratory parameters of a patient with systemic lupus erythematosus prior and during bortezomib therapy (arrow). Time course for laboratory.

Time course for laboratory parameters of a patient with systemic lupus erythematosus prior and during bortezomib therapy (arrow). Time course for laboratory.
Fig. 2 TLR8 is aberrantly expressed on pDCs from SSc patients.

Fig. 2 TLR8 is aberrantly expressed on pDCs from SSc patients.
Correlation between disease activity and phospho-H2AX levels at G0/G1, S and G2 cell-cycle phases in primary CD3+ T cells and monocytes from patients with.

Correlation between disease activity and phospho-H2AX levels at G0/G1, S and G2 cell-cycle phases in primary CD3+ T cells and monocytes from patients with.
Management of Systemic Lupus Erythematosus

Management of Systemic Lupus Erythematosus
Mean Safety of Estrogens in Lupus Erythematosus National Assessment–Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score at the last.

Mean Safety of Estrogens in Lupus Erythematosus National Assessment–Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score at the last.
Immunohistochemistry staining of interferon (IFN)-λ in renal tissue.

Immunohistochemistry staining of interferon (IFN)-λ in renal tissue.
(A) Phospho-H2AX levels are significantly increased in CD4+ T cells, CD8+ T cells and monocytes from SLE compared with those from healthy controls (p=2.16×10−4,

(A) Phospho-H2AX levels are significantly increased in CD4+ T cells, CD8+ T cells and monocytes from SLE compared with those from healthy controls (p=2.16×10−4,
Lupus Foundation of America-Rapid Evaluation of Activity in Lupus (LFA-REAL) comprised seven anchored Visual Analogue Scales (0–100 mm each) and can describe.

Lupus Foundation of America-Rapid Evaluation of Activity in Lupus (LFA-REAL) comprised seven anchored Visual Analogue Scales (0–100 mm each) and can describe.
Deficiency of TLR9 does not affect autoantibody levels but shifts autoantibody specificity. Deficiency of TLR9 does not affect autoantibody levels but.

Deficiency of TLR9 does not affect autoantibody levels but shifts autoantibody specificity. Deficiency of TLR9 does not affect autoantibody levels but.
Association of B cell TLR4 levels to disease activity.

Association of B cell TLR4 levels to disease activity.
Serum osteopontin (OPN) levels in population-based controls and in cases with SLE. Serum levels of OPN, determined by ELISA, were significantly higher.

Serum osteopontin (OPN) levels in population-based controls and in cases with SLE. Serum levels of OPN, determined by ELISA, were significantly higher.
Immunohistochemistry (IHC) staining of interferon (IFN)-λ in renal tissue The figure demonstrates a repeated renal biopsy obtained from a patient after.

Immunohistochemistry (IHC) staining of interferon (IFN)-λ in renal tissue The figure demonstrates a repeated renal biopsy obtained from a patient after.
Correlations of EBV-specific T-cells and disease activity of SLE patients. Correlations of EBV-specific T-cells and disease activity of SLE patients. Correlation.

Correlations of EBV-specific T-cells and disease activity of SLE patients. Correlations of EBV-specific T-cells and disease activity of SLE patients. Correlation.
The pattern of alteration of HCQ, prednisolone and/or ISS drugs by physicians in a patient with a history of major organ involvement from their SLE (renal.

The pattern of alteration of HCQ, prednisolone and/or ISS drugs by physicians in a patient with a history of major organ involvement from their SLE (renal.

Similar presentations

Ads by Google